Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Jul;45(3 Suppl 2):S2-6.
doi: 10.1053/j.seminhematol.2008.07.003.

Treatment of follicular non-Hodgkin's lymphoma: the old and the new

Jonathan W Friedberg  1
Affiliations
Review

Treatment of follicular non-Hodgkin's lymphoma: the old and the new

Jonathan W Friedberg. Semin Hematol. 2008 Jul.

Abstract

Despite remaining an incurable disease, overall survival improvements have been noted in patients with advanced-stage follicular lymphoma. The Follicular Lymphoma International Prognostic Index (FLIPI) is a robust prognostic index in this disease, and continues to provide prognostic information in the rituximab era. Rituximab has significantly changed the management of follicular lymphoma, and the most dramatic impact of rituximab is observed in combination with cytotoxic chemotherapy. However, resistance to rituximab remains a problem, and standard therapy in the rituximab-refractory setting includes radioimmunotherapy, autologous stem cell transplantation, and allogeneic stem cell transplantation. In addition, several novel agents show encouraging activity in follicular lymphoma, including bendamustine, lenalidomide, bortezomib, and other proteasome inhibitors, and BCL2 inhibitors.

PubMed Disclaimer

References

    1. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:7565–7573. - PubMed
    1. Halaas JL, Teruya-Feldstein J, Filippa DA, Chaya M, Naresh KN, Zelenetz AD. The Follicular Lymphoma International Prognostic Index (FLIPI) Is superior to WHO/REAL histological grade for identifying high-risk patients: a retrospective review of the MSKCC experience in 260 patients with follicular lymphoma. Blood. 2004;104 892a (abstr 3268)
    1. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265. - PubMed
    1. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate-or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504–1508. - PubMed
    1. An observational study of treatment, outcomes, and prognosis in patients with follicular non-Hodgkin's lymphoma. [Accessed 1-22-2008]. No authors listed. http://clinicaltrials.gov/ct2/show/NCT00097565.